Virtually all men with metastatic prostate cancer will eventually develop mCRPC, an advanced stage of the disease. The AR-V7 test is the first and only Medicare reimbursed clinically-validated predictive CTC liquid biopsy test for mCRPC.
Our radically different approach is bias-free, a unique rare cell detection engine that can capture, identify and characterize all the circulating tumor cells (CTCs) in a blood sample and see the cancer cells that others miss. The insights gained empower physicians to select the path to confident treatment decisions, targeted for the individual patient, in less time.
Epic Sciences technology can thus see, identify and characterize all the circulating tumor cells (CTCs) in a blood sample, and link their response or resistance to a panoply of drug classes. Specifically, the Epic Sciences' AR-V7 test identifies patients who are likely to be resistant to androgen-directed therapies such as Zytiga® (abiraterone acetate) or Xtandi® (enzalutamide). Thus alerted, physicians will be empowered to make alternative treatment choices to which their patients will most likely respond, while avoiding toxic effects and costs associated with ineffective treatment, and significantly improving outcomes.
Our liquid biopsy test utilizes a blood sample from a common blood draw, which is sent to the Epic Sciences' clinical laboratory.
The sample is processed for characterization of nuclear localized AR V7+ CTCs in our CAP accredited clinical laboratory.
Patient results are reported to the ordering physician, confirming the patient as either AR-V7+ (positive) or AR-V7- (negative).
The AR-V7 Nucleus Detect assay is ideal for late-stage metastatic prostate cancer patients who:
Have received and failed AR-targeted therapy
Have confirmed mCRPC
Are considering additional AR-targeted therapies
For more information visit the Genomic Health Physicians’ Portal.
All tests are performed by Epic Sciences at our centralized, CAP accredited and CLIA-certified laboratory in San Diego, California.